Triptonide

Research use only, not for human use.

A key bioactive small molecule identified in Tripterygium wilfordii Hook F., has a broad spectrum of biological functions.

A key bioactive small molecule identified in Tripterygium wilfordii Hook F., has a broad spectrum of biological functions; effectively inhibits canonical Wnt/β-catenin signaling by targeting the downstream C-terminal transcription domain of β-catenin; upregulates the expression of IL-37; potently inhibits the proliferation of human B-lymphoma Raji and T-lymphoma Jurkat cells with IC50 of 5.7 nM and 4.8 nM, respectively.(In Vitro):Triptonide blocks Wnt/β-catenin signaling via C-terminal transactivation domain of β-catenin, and promots apoptosis in Wnt-dependent cancer cells.Triptonide potently inhibits the proliferation of human B-lymphoma Raji and T-lymphoma Jurkat cells with IC50 of 5.7 nM and 4.8 nM, respectively.Triptonide (2.5-10 nM; 6 days) significantly suppresses B-lymphoma cell colony-forming capability.Triptonide (20 nM; 3 days) promotes apoptosis through activation of PARP and caspase 3, but reduction of BCL2 protein levels in the lymphoma cells.Triptonide (5-10 nM; 72 hours) markedly reduces both total and phosphorylated Lyn proteins, and diminishes Lyn downstream ERK and ATK signal pathways.(In Vivo):Triptonide (5 mg/kg; i.p.; daily; for 34 days) exerts a strong anti-lymphoma effect in mice.

Triptonide blocks Wnt/β-catenin signaling via C-terminal transactivation domain of β-catenin, and promots apoptosis in Wnt-dependent cancer cells.Triptonide potently inhibits the proliferation of human B-lymphoma Raji and T-lymphoma Jurkat cells with IC50 of 5.7 nM and 4.8 nM, respectively.Triptonide (2.5-10 nM; 6 days) significantly suppresses B-lymphoma cell colony-forming capability.Triptonide (20 nM; 3 days) promotes apoptosis through activation of PARP and caspase 3, but reduction of BCL2 protein levels in the lymphoma cells.Triptonide (5-10 nM; 72 hours) markedly reduces both total and phosphorylated Lyn proteins, and diminishes Lyn downstream ERK and ATK signal pathways. Cell Proliferation Assay Cell Line:B-lymphoma Raji cells, T-lymphoma Jurkat cells Concentration:0-80 nM Incubation Time:3 days, 6 days Result:Inhibited lymphoma cell tumorigenic capability in a dose-dependent manner.Apoptosis Analysis Cell Line:Raji cells Concentration:5 nM, 10 nM, 20 nM Incubation Time:3 days Result:Did not significantly induce apoptosis at the effective tumor growth-inhibitory (2.5-10 nM); moderately induced lymphoma cell apoptosis (20 nM).Western Blot Analysis Cell Line:Raji cells Concentration:5 nM, 10 nM, 20 nM Incubation Time:3 days Result:Did not vigorously activated pro-apoptotic proteins PARP and caspase 3 in lymphoma cells (5-10 nM); significantly activated PARP and caspase 3 (20 nM); significantly reduced anti-apoptotic BCL2 levels. RT-PCRCell Line:Raji cells Concentration:5 nM, 10 nM Incubation Time:72 hours Result:Significantly diminished Lyn mRNA levels in the lymphoma cells.

Triptonide (5 mg/kg; i.p.; daily; for 34 days) exerts a strong anti-lymphoma effect in mice. Animal Model:Eight-week-old female NOD/SCID mice (18-22 g), with 3 x 107 Raji cells xenograft Dosage:5 mg/kg Administration:Intraperitoneal injection, daily, for 34 days Result:Potently inhibited lymphoma cell growth and tumorigenic capability.

NSC 165677 | PG 492

Wnt/Notch/Hedgehog

Beta-catenin

Others

Cancer

——

38647-11-9

358.3851

C20H22O6

>98% (HPLC)

10 mM in DMSO

O=C1OCC2=C1CC[C@@]3(C)[C@H]2C[C@H]4[C@]5(O4)[C@@]3(O6)[C@@H]6[C@H](O7)[C@@]7(C(C)C)C5=O

Trisoxireno[4b,5:6,7:8a,9]phenanthro[1,2-c]furan-1,6(3H,6aH)-dione, 3b,4,4a,7a,7b,8b,9,10-octahydro-8b-methyl-6a-(1-methylethyl)-, (3bS,4aS,5aS,6aS,7aS,7bS,8aS,8bS)-

(-20℃)

With Ice Pack

≥ 2 years